If you'd invested $6,000 in the ASX 300 stock in January, you'd have $22,551 today!

Shareholders in the ASX 300 stock have the FDA to thank for much of this year's success.

| More on:
A man wearing a white coat holds his hands up and mouth open with joy.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

The S&P/ASX 300 Index (ASX: XKO) is up a respectable 7.7% in 2024, but this ASX 300 stock has left those gains far behind.

The high-flying stock in question is biotech company Mesoblast Ltd (ASX: MSB).

On 3 January, the Mesoblast share price closed the day down 4.9% at 29 cents.

That means you could have snapped up 20,689 Mesoblast shares with a $6,000 investment.

In late morning trade today, those same shares were swapping hands for $1.09 apiece, up 275.9%.

If you had decided to sell those shares then, you could have turned that $6,000 investment in this ASX 300 stock January into $22,551.01 today.

Created with Highcharts 11.4.3Mesoblast PriceZoom1M3M6MYTD1Y5Y10YALL1 Jan 202414 Jun 2025Zoom ▾Jan '24Mar '24May '24Jul '24Sep '24Nov '24Jan '25Mar '25May '25Jan '24Jan '24May '24May '24Sep '24Sep '24Jan '25Jan '25May '25May '25www.fool.com.au

Boom!

Here's what's been sending the stock flying higher.

FDA helps send ASX 300 stock soaring

Most of the meteoric gains in the Mesoblast share price this year came in March and April.

In late March, the ASX 300 stock reported on the progress of its remestemcel-L treatment with receiving United States Food and Drug Administration (FDA) approval.

Mesoblast's remestemcel-L is intended to treat inflammatory diseases, including steroid-refractory acute graft versus host disease and biologic-resistant inflammatory bowel disease.

On 26 March, Mesoblast announced the FDA had determined that the results of the additional clinical data from its phase 3 study sufficed to support the resubmission of Mesoblast's proposed Biologics License Application (BLA) for remestemcel-L.

Shares in the ASX 300 stock closed up 45.5% on the day of the FDA announcement, with investors clearly excited about the drug's potential in the world's top economy.

And as word spread, Mesoblast shares kept on charging higher in March, leaping 71.2% in a single day on 2 April despite no fresh news coming out from the company.

What's been happening lately?

Mesoblast shares traded at 52-week plus highs on 23 July, closing the day at $1.31.

While the ASX 300 stock has retraced from that level, shares regained a positive trajectory over the past month, up 15% since 27 August.

Investors initially reacted somewhat negatively to Mesoblast's FY 2024 results, reported on 29 August, with shares closing down 0.5% on the day.

However, the next day the market seemed to have second thoughts about that, with the Mesoblast share price blasting 8.4% higher on 30 August.

Key metrics from the company's full-year results included a 17% year-on-year decline in revenue to US$5.9 million. This was primarily due to lower royalties on Temcell HS sales in Japan.

Despite sizeable cost reductions, Mesoblast reported a net loss after tax of $88.1 million, up from an $81.8 million net loss in FY 2023.

But investors clearly still see this as an ASX 300 growth stock, priced with potential future commercial successes in mind.

Indeed, as Mesoblast CEO Silviu Itescu said on the day of the results announcement, "We are in active discussions with the agency [FDA] and anticipate a decision prior to or on the … goal date of January 7, 2025."

Itescu added:

Concurrently we are implementing a go-to-market plan to bring RYONCIL [remestemcel-L] to the many children suffering with this devastating disease, picking up the substantial amount of work completed last year.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors were nervous this Friday, ending the week on a sour note.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Gainers

Why EOS, Evolution Mining, Renascor, and Woodside shares are jumping today

These shares are ending the week on a high. But why?

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a volatile, but negative day for ASX investors this Thursday.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Guess which ASX 200 stock turned $5,000 into $34,264 in just three years!

Investors have been piling into this ASX 200 stock for years, sending the share price soaring.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Share Gainers

Why Beach Energy, Meeka Metals, Monash IVF, and Qantas shares are racing higher today

These shares are having a better day than most on Thursday. But why?

Read more »

Rising gold share price represented by a green arrow on piles of gold block.
Share Gainers

2 ASX All Ords stocks that would already have more than doubled your money this year

These ASX All Ords stocks have gained 126% and 145% year to date. But how?

Read more »

Ten smiling business people wave to the camera after receiving some winning company news.
Share Gainers

Here are the top 10 ASX 200 shares today

It was an historic day for the ASX, with the market setting a new record.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why Fletcher Building, Johns Lyng, Pilbara Minerals, and Zip shares are charging higher

These shares are having a strong session on hump day. But why?

Read more »